Cargando…

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC

BACKGROUND: PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are acceptably used in assessment of Olaparib response, there are still evident limitations in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Chenggong, Cao, Wenyu, Qiu, Chunping, Li, Chengcheng, Dongol, Samina, Zhang, Zhiwei, Dong, Ruifen, Song, Kun, Yang, Xingsheng, Zhang, Qing, Kong, Beihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995078/ https://www.ncbi.nlm.nih.gov/pubmed/32005272 http://dx.doi.org/10.1186/s13045-020-0844-0

Ejemplares similares

Upregulated MELK Leads to Doxorubicin Chemoresistance and M2 Macrophage Polarization via the miR-34a/JAK2/STAT3 Pathway in Uterine Leiomyosarcoma
por: Zhang, Zhiwei, et al.
Publicado: (2020)

CCNG1 (Cyclin G1) regulation by mutant‐P53 via induction of Notch3 expression promotes high‐grade serous ovarian cancer (HGSOC) tumorigenesis and progression
por: Xu, Ying, et al.
Publicado: (2018)

IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer
por: Dongol, Samina, et al.
Publicado: (2020)

Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review
por: Li, Congcong, et al.
Publicado: (2019)

PARPi after PARPi in epithelial ovarian cancer
por: Essel, K.G., et al.
Publicado: (2021)

Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
por: Hewitt, Graeme, et al.
Publicado: (2021)

Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy
por: Sheta, Razan, et al.
Publicado: (2020)

BETting on combination to overcome PARPi resistance
por: Zhang, Youyou, et al.
Publicado: (2017)

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
por: Rose, Peter G, et al.
Publicado: (2021)

Pyridoxal phosphate synthases PdxS/PdxT are required for Actinobacillus pleuropneumoniae viability, stress tolerance and virulence
por: Xie, Fang, et al.
Publicado: (2017)

Progesterone prevents HGSOC by promoting precancerous cell pyroptosis via inducing fibroblast paracrine
por: Wu, Nayiyuan, et al.
Publicado: (2023)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

3D dynamic cultures of HGSOC organoids to model innovative and standard therapies
por: Cavarzerani, Enrico, et al.
Publicado: (2023)

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
por: Irwin, Christopher P., et al.
Publicado: (2014)

[(18)F]PARPi Imaging Is Not Affected by HPV Status In Vitro
por: Guru, Navjot, et al.
Publicado: (2021)

Fully Automated, High-Dose Radiosynthesis of [(18)F]PARPi
por: Pacelli, Anna, et al.
Publicado: (2022)

Construction of PARPi Resistance-related Competing Endogenous RNA Network
por: Kong, Lili, et al.
Publicado: (2022)

Model Cell Lines and Tissues of Different HGSOC Subtypes Differ in Local Estrogen Biosynthesis
por: Pavlič, Renata, et al.
Publicado: (2022)

Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes
por: Cunnea, Paula, et al.
Publicado: (2023)

Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
por: Zhang, Qing, et al.
Publicado: (2017)

A chemotherapy response prediction model derived from tumor-promoting B and Tregs and proinflammatory macrophages in HGSOC
por: Xi, Yue, et al.
Publicado: (2023)

Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior
por: Reyes, Henry D., et al.
Publicado: (2019)

RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC
por: Xu, Jing, et al.
Publicado: (2023)

Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer
por: Klotz, Daniel Martin, et al.
Publicado: (2023)

SAT-509 Sudden Onset of Malabsorption
por: Mroueh, Gabriela, et al.
Publicado: (2020)

Immunotherapy in endometrial cancer: rationale, practice and perspectives
por: Cao, Wenyu, et al.
Publicado: (2021)

x509-free access to WLCG resources
por: Short, H, et al.
Publicado: (2017)

WLCG Authorisation from X.509 to Tokens
por: Bockelman, Brian, et al.
Publicado: (2020)

509 Pilot Projects as Catalysts for Research Initiatives
por: Patel, Milan, et al.
Publicado: (2022)

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
por: Madariaga, Ainhoa, et al.
Publicado: (2020)

Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts
por: Di Raimo, Tania, et al.
Publicado: (2020)

ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance
por: O’Sullivan, Julia, et al.
Publicado: (2023)

HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients
por: Li, Lei, et al.
Publicado: (2023)

Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial
por: Chen, Jiayu, et al.
Publicado: (2022)

The Expression and Role Analysis of Methylation-Regulated Differentially Expressed Gene UBE2C in Pan-Cancer, Especially for HGSOC
por: Li, Jiajia, et al.
Publicado: (2022)

MRE11:p.K464R mutation mediates olaparib resistance by enhancing DNA damage repair in HGSOC
por: Zhuang, Xucui, et al.
Publicado: (2023)

Low E2F2 activity is associated with high genomic instability and PARPi resistance
por: Rennhack, Jonathan P., et al.
Publicado: (2020)

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
por: Moubarak, Malak, et al.
Publicado: (2022)

SAT-509 Denosumab Use in Tertiary Hiperparathyroidism with Fracture
por: Coy, Andres, et al.
Publicado: (2019)

Clinico-genetic findings in 509 frontotemporal dementia patients
por: Wagner, Matias, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ghq9sh9recovfaeg9rmgs6gg9g